Global Drugs for Herpes Labialis (Oral Herpes) Market | Growth Market Reports
                     Global Drugs for Herpes Labialis (Oral 
Herpes) Market By Product Type (Aciclovir, 
Valacyclovir, Famciclovir, Docosano), By 
Medication Type (Prescribed (Rx), OTC), By 
Dosage Forms (Ointments/Cream/Gels/Lip 
Balm , Medicines, Injections), By Routes of 
Administration (Topical, Oral, Parenteral ), By 
Region (North America, Europe, Asia Pacific, 
Latin America, Middle East & Asia)
• The global drugs for herpes labialis (oral herpes) market 
was valued at USD 925.4 Million in 2019 and is projected 
to reach USD X,XX2.9 Million by 2027, expanding at a 
CAGR of 4.6% during the forecast period. The market is 
driven by factors such as increasing prevalence of herpes 
labialis among children and adults across the globe, 
innovations in drug types and modes of action, soaring 
penetration of generics, frequent transformations in 
disease treatment, and growing consumer awareness. 
However, stringent government regulations regarding 
drug approvals and lack of awareness and knowledge 
about herpes labialis are key restraints of this market. 
Drugs for Herpes Labialis (Oral Herpes) Market 
Outlook
• Increasing R&D is estimated to create lucrative opportunities in the 
near future. The emergence of novel therapies is boosting the 
growth of the market. Recent market trends include collaborations 
between market players and universities, and mergers & 
acquisitions among the leading companies.
On the basis of product types, the drugs for herpes labialis (oral 
herpes) market is segmented into aciclovir, valacyclovir, famciclovir, 
docosanol, and penciclovir. The acyclovir segment is estimated to 
hold a large share of the market during the forecast period, as these 
drugs are widely used and trusted due to their highly effective 
outcomes. Valacyclovir is considered to be more effective than the 
previously used drugs such as aciclovir due to requirement of 
limited number of dosages, long-term effect on the infection, and 
immediate effect on virus infection; ,therefore the segment is 
anticipated to expand at a high CAGR of X.1% during the forecast 
period.
• Based of medication types, the drugs for herpes labialis (oral 
herpes) market is bifurcated into prescribed (Rx) and OTC. The 
prescribed (Rx) segment is projected to constitute a X4.8% share of 
the market by 2027 and is anticipated to expand at a CAGR of X.7% 
due to the increase in incidences of herpes labialis, which in turn, 
boosts the usage of the prescribed medication. 
On the basis of dosage forms, the market is divided into 
ointments/creams/gels/lip balms, medicines, and injections. The 
medicines segment holds a major share of the market and is 
projected to expand at high CAGR, medicines are considered to be 
effective and have a high success rate of recovery. 
Ointments/creams/gels/lip balms are considered to be effective for 
instantly providing pain relief on the site of infections and is usually 
prescribed with the medicines to increase the rate of recovery. This, 
in turn, increases the demand for the ointments/creams/gels/lip 
balms.
• On the basis of routes of administration, the drugs for herpes 
labialis (oral herpes) market is segregated into topical, oral, 
and parenteral. The oral segment holds a major share of the 
market and is projected to expand at a substantial CAGR 
during the forecast period, as it is a highly preferred method 
of consuming medications and is easy to consume. Oral 
medications are usually prescribed with the combination of 
topically administered drugs, which in turn, is expected to 
drive the demand for oral and topical medications with CAGR 
of X.8% and X.5%, respectively, during the forecast period.
Drugs for Herpes Labialis (Oral Herpes) Market 
Segmet
• In terms of regions, the global drugs for herpes labialis (oral 
herpes) market has been segmented into North America, 
Europe, Asia Pacific, Latin America, and Middle East & Africa. 
North America is a promising region for the market. The 
market is this region constituted a X4.6% share of the global 
market in 2020. The market in the region is projected to 
expand at a CAGR of X.4% during the forecast period due to 
the increase in the demand for drugs for herpes labialis, the 
presence of a well-developed pharmaceutical infrastructure 
for R&D activities, and the presence of major players in this 
region. The market in Asia Pacific is projected to expand at a 
CAGR of X.2% due to increased government spending, rising 
FDI policies, and growing incidences of the herpes labialis in 
the region.
Drugs for Herpes Labialis (Oral Herpes) Market 
Regional Analysis
Key players in the market include Pfizer INC., Mylan N.V., Teva Pharmaceutical 
Industries Ltd. They are considered as key drug manufacturers in this market 
based on their investments in R&D, segmental revenue, regional presence, 
and supply chain management system.
Drugs for Herpes Labialis (Oral Herpes) Market 
Report Attribute
Report Attribute Report Details
Base Year 2019
Historical Data 2015
Forecast Year 2027
Growth Rate 4.6%
Market Value in 2019 USD 925.4 Million
By Region (North America, Europe, Asia Pacific, Latin America, Middle 
Regional scope East & Asia)
By Product Type (Aciclovir, Valacyclovir, Famciclovir, Docosano), By 
Medication Type (Prescribed (Rx), OTC), By Dosage Forms 
Segments covered (Ointments/Cream/Gels/Lip Balm , Medicines, Injections), By Routes 
of Administration (Topical, Oral, Parenteal), By Region (North America, 
Europe, Asia Pacific, Latin America, Middle East & Asia)
Apotex Inc, Pfizer INC, Mylan N.V., Novartis AG, Teva Pharmaceutical 
Key Companies Profiled Industries Ltd, Zydus Cadila, Hikma Pharmaceuticals PLC, Livzon, 
Torrent Pharmaceuticals Ltd, Blistex Inc